News | December 18, 2014

Topera Receives Most Innovative New Product Award for 3-D Arrythmia Mapping System

Product designed to improve patient outcomes by enabling electrophysiologists to view dynamic representation of the electrical activity of the heart

EP Lab, Atrial Fibrilation, RhythmView 3-D Mapping System, MIP Award

Image courtesy of Topera


December 18, 2014 — Topera, Inc. announced that its RhythmView 3-D Mapping System received the Most Innovative New Product (MIP) Award at the 2014 CONNECT MIP Awards.

Topera’s RhythmView 3-D Mapping System received San Diego’s most prestigious honor for technology and life sciences innovation in the Pharmaceutical Drugs and Medical Devices category, based on its innovative electrophysiology platform to improve the diagnosis and treatment of complex cardiac arrhythmias including atrial fibrillation, the most common heart rhythm disorder in the world, afflicting 8 million people in the United States and Europe alone.

Topera’s 3-D analysis and mapping system assists electrophysiologists in the identification of the electrical source of complex cardiac arrhythmias. With the Topera 3-D Mapping System patient outcomes can be potentially improved by enabling electrophysiologists to view a dynamic representation of the electrical activity of the heart, supporting the diagnosis of the arrhythmia source and treatment planning for a variety of heart rhythm disorders including atrial fibrillation, atrial flutter, atrial tachycardia and ventricular tachycardia.

For a complete list of winners: wwww.connect.org

For more information: www.toperamedical.com

 

 


Related Content

News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
Subscribe Now